T Cell Death and Transplantation Tolerance  by Li, Xian Chang et al.
Immunity, Vol. 14, 407–416, April, 2001, Copyright ª 2001 by Cell Press
T Cell Death Review
and Transplantation Tolerance
plementary have been proposed as the basis of trans-
plantation tolerance. These mechanisms can be placed
into one of two categories: (1) deletional mechanisms
Xian Chang Li,*§ Terry B. Strom,*‡§
Laurence A. Turka,‡†§ and Andrew D. Wells†§
*Department of Medicine
Beth Israel Deaconess Medical Center in which donor-reactive clones are destroyed and (2)
nondeletional immunoregulatory states, including clonalHarvard Medical School
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University of Pennsylvania clones has been altered.
To varying degrees, each of these mechanisms hasPhiladelphia, Pennsylvania 19104
been demonstrated to play a role in the acquisition and
maintenance of self-tolerance. Regarding nondeletional
mechanisms, for example, evidence from mouse modelsTransplantation Tolerance—Introduction
implicates CD41CD251 and/or CD41CD45RBlo cells, whichDefinition
manifest suppressor/regulatory function, in the preven-Immunologic tolerance may be defined as a state in which
tion of autoimmune disorders, such as inflammatory co-(1) the immune system does not mount a pathologic re-
litis (Groux and Powrie, 1999). In the case of deletionalsponse against a specific antigen (or antigens), (2) there
mechanisms, the situation is complex because deletionis no requirement for ongoing exogenous immunosup-
can occur in two distinct anatomic and functional com-pression, and (3) responses to other antigens are main-
partments: the thymus (central) and the periphery. Thetained. For over a century, it has been appreciated that
thymus is the primary site where autoreactive cells areindividuals rarely make pathogenic antibodies against
deleted. Potentially autoreactive T cells that fail to beself-antigens, even after deliberate immunization. More
deleted in the thymus either because deletion is activelyrecently, we have recognized that this apparent absence
inhibited or because the antigen is not expressed withinof an immune response is not merely an act of omission
the thymic compartment can still undergo deletion inbut also one of commission and that active immuno-
the periphery. In fact, in animal models (and rare humanregulatory mechanisms participate. Thus, an immune
examples) in which peripheral (but not central) deletionresponse against self-antigens can be protective or de-
is impaired (e.g., disruption of the Fas/FasL pathway,structive. When this balance breaks down, the result is
IL-2 deficiency, etc.), the result is dramatic expansionautoimmunity. When the response is directed against a
of the peripheral lymphoid compartments and accumu-transplanted organ or tissue, the result is graft rejection.
lation of activated T and B lymphocytes. Such lympho-There have been many spectacular successes in de-
cytes are likely to have autoreactive potential, as animalsliberate attempts to stimulate the immune response
bearing these mutations frequently develop various au-(e.g., numerous vaccines) and other instances in which
toimmune disorders.the results have been suboptimal (e.g., other vaccines
Implicationsor cancer immunotherapy). The history of attempts to
Tolerance to self and tolerance to transplanted organssuppress the immune response similarly contains both
and tissues share several common features, includingsuccesses and failures. Notably, however, the suc-
the need to tolerize to an enormous number of antigens.cesses are largely limited to the use of global nonspe-
In the case of self-tolerance, these consist of myriadcific immunosuppression. Instances in which true anti-
peptides generated from self-proteins complexed togen-specific tolerance has deliberately been created
various self-MHC molecules. In the case of transplanta-and rigorously proven, either in the treatment of autoim-
tion, these consist of both self- and nonself-proteinsmunity or transplantation, have been few and far be-
bound to allo-MHC molecules (direct allorecognition)tween. As Nossal has pointed out, for “. . .the situation
as well as the smaller contribution of nonself-proteinsof a successful, long-term renal allograft. Here it might
bound to self-MHC molecules (indirect allorecognition).seem that classical tolerance has been induced but in
It has been estimated that the number of T cells thatreality an armed truce exists, as the withdrawal of the
are deleted during development in the thymus is up torequired modest doses of immunosuppressive drugs
90%–99%. Due to the high precursor frequency of cellsquickly demonstrates” (Nossal, 1989).
that recognize allo-MHC molecules (Suchin et al., 2001),Mechanisms
this is roughly the magnitude of alloreactive cells thatIt is an axiom of faith of most transplant immunologists
would need to be dealt with in order to induce trans-that, when successful strategies for the induction and
plantation tolerance. This consideration has suggestedmaintenance of transplantation tolerance are devel-
that deletional mechanisms would be critical for the in-oped, they will exploit the normal homeostatic mecha-
duction of transplantation tolerance. Clearly, deletionalnisms that maintain self-tolerance. Several mechanisms
tolerance is the major mechanism operative in so-callednot necessarily mutually exclusive and probably com-
“central” tolerogenic approaches, which rely on either
the direct introduction of allogeneic cells into the thymus
or, more commonly, the creation of mixed hematopoietic‡ To whom correspondence should be addressed (e-mail: tstrom@
chimerism with subsequent seeding of the thymus bycaregroup.harvard.edu [T. B. S.], turka@mail.med.upenn.edu [L. A. T.]).
§ These authors contributed equally to this work. allogeneic cells (Ildstad and Sachs, 1984). However, ac-
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cumulating evidence suggests that, even in peripheral Depletion plus Creation of Hematopoietic Chimerism.
One of the most effective ways to deal with continuedtolerogenic approaches, which have been thought to
thymic production of alloreactive T cells is central clonalrely on clonal anergy and immunoregulation, a deletional
deletion. To this end, lymphoablative treatments havecomponent is required to deal with the large burden of
been used as a backdrop to create a mixed hematopoi-alloreactive cells (Li et al., 1999; Wells et al., 1999). This
etic chimeric state (Figure 1). In this instance, donorarticle will discuss insights from experimental animal
cells seed the thymus, and maturing donor-reactivemodels regarding the induction and the maintenance of
T cell clones are deleted through intrathymic apoptosistransplantation tolerance, review the conceptual basis
(Wekerle et al., 1998). The ability of donor bone marrowfor a model that “requires” T cell death in transplantation
to engraft can be enhanced by facilitating cells and bytolerance induction, discuss the predictions that arise
veto cells, which typically are CD81 and act through thefrom such a model and the evidence to support them,
Fas ligand–Fas-mediated pathway (George et al., 1998;and review the implications of this model for the devel-
Gandy et al., 1999; Reich-Zeliger et al., 2000). Thus, anopment of clinical strategies.
intact Fas–FasL system may be necessary to establish
chimerism and thus induce central tolerance. As will be
discussed below, the mechanisms of peripheral deletionTemporal Order of Events in Alloimmunity
appear to differ at least in the sense that Fas is notWhile transplantation tolerance cannot be reliably cre-
necessarily required.ated in humans or nonhuman primates, it is relatively
Nonlymphoablative Treatments. Agents that inhibiteasier to create in smaller animals. Over the last several
the function of lymphocytes without inherently depletingdecades, a variety of strategies have been applied suc-
them can also produce tolerance in many models. Thiscessfully to rodent models of tissue and organ trans-
has been demonstrated for a wide variety of treatments.plantation, and these have revealed a number of impor-
However, as we will argue below, a component of T celltant mechanistic insights. As viewed from the highest
deletion is likely to be essential to these approaches.vantage point, we have learned that the induction and
The Ignorance Phasemaintenance of tolerance to MHC-mismatched organ
In the absence of massive deletion of mature T celltransplants is frequently a multistep, multifaceted pro-
clones established in parallel to the creation of a statecess that encompasses both clonally depletive and im-
of mixed chimerism, a period of apparent immunologicmunoregulatory processes. In hosts that achieve donor-
ignorance often follows cessation of active therapyspecific allograft tolerance, the allograft response often
(Scully et al., 1994) (Figure 2). If “unperturbed,” the suc-can be divided into three temporally and mechanistically
cessfully treated host will go on to achieve tolerance indistinct stages: induction, functional ignorance, and true
the future. In contrast to true tolerance, this stage istolerance (Figures 1 and 2).
only metastable, as a challenge with highly immunogenicThe Induction Phase
donor tissues, donor antigen(s) delivered under immu-This refers to the period in which the successfully treated
nogenic conditions, or IL-2 triggers graft rejection (Tranhost receives active treatment. Traditionally, these treat-
et al., 1997). Behind these descriptive observations layments are classified based on whether or not they di-
a great deal of ignorance on the part of researchers re-rectly lyse/deplete T cells.
garding ignorance on the part of the immune system.Depletion. Elimination of mature T cells can be achieved
The most likely scenario is one in which central deletiondirectly by depleting antibodies, immunotoxins, and/or
of newly produced alloreactive clones is incomplete andlymphoid irradiation. Depletion is inherently nonselec-
there is a competition between newly exported maturetive, as there is no reliably a priori way to target only al-
alloreactive T cells and immunoregulatory systems thatloreactive clones. Furthermore, assuming that the host
are developing to neutralize them.has normal thymic function, new alloreactive T cells will
The Tolerance Phase
develop, and these, of course, need to be either deleted
True tolerance is achieved when challenge with donor
or inactivated in order to maintain the tolerant state.
tissues can no longer elicit graft rejection, although third-
Alloreactive T cells that escape from the thymus in hosts party tissues are readily rejected (Figure 2). Unless com-
with an immature immune system, a circumstance com- plete central deletion of alloreactive cells is achieved,
parable to the state occurring after lymphoablative ther- peripheral mechanisms are required to maintain the tol-
apy, are particularly susceptible to induction of periph- erant state, and these can include peripheral deletion
eral tolerance (Matzinger and Anderson, 2001). Thus, and/or immunoregulation. There is clear evidence for
the conditions involved in lymphocyte repopulation im- peripheral deletion in some models of transplantation
mediately following lymphoablative treatment favor but tolerance, although whether or not it continues to occur
do not insure tolerance induction. Moreover, following this late in the game is not known. In contrast, immu-
immune reconstitution, the new alloreactive cells that noregulatory mechanisms have been unequivocally
continue to be exported from the thymus exist in the demonstrated to play a role in maintaining established
context of a now mature immune system. Experimental tolerance. CD41 cell-dependent donor tissue–protective
models have clearly demonstrated that thymectomized immune responses are present in hosts with nondele-
animals are far more susceptible to tolerance induction tional states of peripheral tolerance (Scully et al., 1994;
than euthymic ones. Thus, a principal tenet of transplant Yin and Fathman, 1995). In such circumstances, the toler-
immunologists is the need to disarm or delete newly ant state can be rapidly lost upon removal of the donor
produced T cells. A stable system to do so that is self- graft. Hence, peripheral tolerance is maintained as an
maintaining (i.e., does not require ongoing or periodic active T cell–dependent tissue-protective response,
much as normal self-tolerance.therapy) is a prerequisite of tolerance.
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Figure 1. Deletion Occurs during Both Central and Peripheral Tolerance Induction
During the creation of mixed hematopoietic chimerism, preexisting peripheral donor-reactive T cells are eliminated by treatments such as
irradiation, costimulatory blockade, or depleting antibodies. The subsequent engraftment of donor bone marrow is facilitated by donor-derived
facilitating cells and veto cells. The latter delete recipient antidonor T cells through a Fas-dependent mechanism. Once donor marrow has
engrafted, ongoing central deletion of donor-reactive thymocytes serves to prevent rejection.
Immune Regulation during Transplant Responses have regulatory properties, including CD41 T cells, CD81
T cells, TCR1CD42CD82 cells, veto-like cells, and den-Immune regulation (suppression) has long been recog-
nized to occur in the context of transplantation toler- dritic cells (Gandy et al., 1999; Reich-Zeliger et al., 2000;
Zhang et al., 2000). Efforts to further characterize theseance. A classical example is the demonstration of “infec-
tious tolerance” in transplantation (Qin et al., 1993). Mice cells are hampered by difficulties to clone such cells in
vitro and by the lack of specific phenotypic markers thatbearing minor antigen-mismatched skin allografts can be
readily tolerized by nondepleting anti-CD4 plus anti-CD8 distinguish them from other cells. Moreover, the means
by which regulatory cells suppress immune activationmAbs. T cells from tolerant mice can passively transfer
the tolerant state to naive mice carrying donor-specific and maintain antigen-specific tolerance are not fully
defined and undoubtedly vary with cell type. In someskin allografts, even in the absence of initial tolerizing
therapy, suggesting the existence of powerful regulatory instances, regulatory cells may compete with antigen-
specific T cells for antigen-presenting cells (APCs) andT cells that actively suppress T cell activation and allo-
graft rejection. Such regulatory T cells can also induce T cell growth factors in vivo (Lombardi et al., 1994). In
other models, immune suppression is critically depen-tolerance to third-party MHC-mismatched allografts,
provided that the allograft is from an F1 hybrid mouse dent on CD41 T cells and is mediated by cytokine-driven
immune deviation. For example, allograft tolerance cre-crossed with the original tolerant strain (Wise et al.,
1998), a phenomenon called “linked suppression.” ated by nondepleting anti-CD4 and anti-CD8 mAbs, a pro-
tocol that induces infectious tolerance, can be impairedAlthough evidence supporting active immune sup-
pression in transplantation tolerance is compelling, the by neutralizing IL-4 (Davies et al., 1996). Moreover, the
ability of CD41 T cells to passively transfer tolerance toprecise identity of regulatory cells remains obscure. In
animal models, many cell types have been shown to a secondary host was abolished by blocking IL-4 in
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Figure 2. Interaction of Immunoregulation and Deletion
The induction phase of immune tolerance is typically characterized by some form of therapy that either directly (central approaches) or
indirectly (peripheral approaches) deletes alloreactive T cells. This deletion is important to enable the emerging population of immunoregulatory
cells to establish control and enforce a stable state of immune tolerance.
the primary recipients, although such treatment made possible metastable ignorance phase in between (Fig-
ure 2). The induction phase is characterized by the lackminimal impact on the survival of allografts in the primary
hosts (Bushell et al., 1999). of acute graft rejection, but it can be easily disrupted.
At later time points following transplantation, toleranceIt remains puzzling as to how cytokine-driven immu-
nosuppression could confer the fine antigen specificity cannot be reversed and is imposed, rather, by regulatory
T cells that can transfer donor-specific tolerance to naiveby which transplantation tolerance is defined, although
a recent study demonstrates how regulatory cells that recipients (Qin et al., 1993). Therefore, immunologic tol-
erance is most likely the result of (1) early mechanismsact via a cell contact–dependent mechanism may func-
tion. This study used a TCR transgenic model in which that facilitate graft acceptance as well as (2) long-term
active immunosuppression can be firmly established by mechanisms involving an immunoregulatory state that
donor-specific transfusion (Zhang et al., 2000). Regula- actively opposes T cell–mediated immune responses. The
tory cells established under such conditions induced requirement for T cell apoptosis in the induction of toler-
apoptosis of activated donor-specific CD81 T cells via ance may therefore be manifested during either the in-
a Fas-dependent pathway. Such regulatory cells killed duction phase or the maintenance phase or during both.
activated donor-specific T cells but not T cells activated A number of observations suggest that the ability of
by third-party alloantigens, suggesting the requirement immunoregulation to induce tolerance (as opposed to
for antigen-specific recognition in the process of im- maintain a tolerant state—see below) is limited. Mere
mune suppression. It appears that these regulatory cells existence of potent immunoregulatory cells does not
acquire alloantigens from APCs, upregulate FasL, and mean that they have prevented rejection. Perhaps the
turn themselves into veto cells. best examples of this are studies in which suppressor
cells, which can prolong graft survival upon adoptive
transfer to naive graft recipients, are actually harvestedDeath Sets the Stage for Immunoregulation to Act
from animals that are rejecting their grafts (SchneiderAs discussed above, the process by which transplanta-
et al., 1986)! This is probably a specialized example oftion tolerance is established can often be separated into
at least two phases: induction and maintenance, with a the general phenomenon in which immunoregulatory
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systems develop during the course of, and are an inte- inhibited, and treatment regimens that normally induce
tolerance instead result in graft rejection. We proposegral part of, the immune response itself. However, by
the time the immunoregulatory system has developed, that apoptotic reduction of this extraordinarily large pool
of potentially destructive T cells must occur in order forthe damage has been done. These studies can be inter-
preted to indicate either that immunoregulatory cells allograft acceptance to be achieved. The few alloreac-
tive T cells that remain may then be effectively controlledalone are not able to induce tolerance or that the pace
of events is such that rejection outstrips the generation through immunoregulatory mechanisms, and stable, do-
nor-specific tolerance may be subsequently achievedof such cells. The latter hypothesis would suggest that
the deliberate in vivo generation of immunoregulatory (Figure 2).
This hypothesis regarding the importance of T cellcells early in the course of transplantation would be
able to induce tolerance. Indeed, several groups have pool size in the decision between immunity and toler-
ance is further supported by studies in several distinctstudied whether or not the deliberate and early creation
of an immunoregulatory state can modulate an immune experimental models in which susceptibility to tolerance
induction is associated with low frequencies of antigen-response in vivo. Most of these studies have utilized
models in which the pathogenic response is associated reactive T cells. In one model, systemic administration
of antigen in vivo leads to abortive activation and periph-with Th1 cells and their cytokine products at the site of
injury, including transplant rejection, experimental aller- eral deletion of peptide-specific T cells. The few cells
that remain after the deletion phase (less than 1/2000gic encephalomyelitis (EAE), and autoimmune nonobese
diabetic (NOD) mice. In these studies, Th1!Th2 immune of peripheral lymph node T cells) are nonproliferative
and, as a population, are unable to mediate functionaldeviation, created by exogenous cytokines, Th2 cell ad-
ministration, transgenic cytokine delivery, or gene ther- memory responses, such as help for the production of
antibody by antigen-specific B cells (Malvey et al.,apy, has been able to prevent or reverse autoimmunity
in a number of models (Kuchroo et al., 1995; Gallichan 1998b). However, if the pool of hyporesponsive T cells
is increased in this model z100-fold to a frequency ofet al., 1999). Yet, this approach has proven futile in most
transplantation models (Piccotti et al., 1997; Li et al., z5% (1/20 peripheral T cells), in this case, not by inhib-
iting T cell apoptosis but instead by transferring large1998). We believe that this paradox can be understood
by considering the size of the T cell pool that needs to numbers of antigen-specific T cells from tolerized do-
nors into naive recipients, the population then containsbe restrained.
The proportion of the peripheral T cell repertoire that enough differentiated Th cells to subsequently mediate
B cell help (Malvey et al., 1998a). A second experimentalcan respond to allogeneic MHC has been the subject
of considerable investigation for many years. Widely approach takes advantage of the disparate frequency
of T cells reactive against a major versus a minor histo-varying estimates were reported by investigators using
a variety of different techniques. However, recent stud- compatibility complex mismatch, situations in which the
size of the alloreactive T cell pool may differ by at leasties in which it has been possible to study the function
of individual T cells responding to alloantigens in vivo 100-fold (our unpublished observations). During trans-
plantation or autoimmune disease, tissue destructionshow that the alloreactive T cell precursor frequency
may be as high as 1 in 20 peripheral T cells (Suchin et and/or rejection is associated with a proinflammatory
Th1 response, while tolerance induced by costimulatoryal., 2001). This high number arises from several consid-
erations, including the ability of T cells to directly recog- blockade is preferentially associated with an antiinflam-
matory Th2 (Sayegh et al., 1995). Indeed, inhibition ofnize intact allo-MHC molecules, the existence of multiple
MHC and minor histocompatibility mismatches between Th1 differentiation per se is successful in inducing long-
term acceptance of minor histocompatibility complex–most donor–recipient combinations, and, at least in
mouse models, the response to donor superantigens mismatched allografts and in abrogating autoimmune
diabetes without the need for additional therapeutic in-not shared by the recipient (our unpublished data). Thus,
in the case of MHC-mismatched transplantation, the tervention. However, overt immune deviation by itself
during transplantation across a major histocompatibilityfrequency of alloreactive T cells is at least five orders
of magnitude greater than the frequency of peptide- complex barrier is unable to inhibit allograft rejection
(Mueller et al., 1997; Piccotti et al., 1997; Li et al., 1998).specific T cells responding to a nominal antigen (roughly
1 in 106 peripheral T cells) and is likely to be much higher It is also noteworthy that infectious tolerance, which is
induced and maintained by regulatory cells, was first de-than the frequency of autoreactive T cells that exist at
the time an autoimmune process is initiated. Regimens scribed in minor histocompatibility–mismatched sys-
tems and not in MHC-mismatched ones (Qin et al., 1993).that block acute allograft rejection, such as costimu-
latory blockade or rapamycin treatment, specifically Recently, infectious tolerance has been reported to pre-
vent graft rejection across an MHC mismatch (Wise etreduce the survival capacity of T cells responding to
alloantigens in vivo (Li et al., 1999), leading to a 10- to al., 1998). This required the adoptive transfer of 50 mil-
lion regulatory cells into the recipient mouse. This ele-1000-fold reduction in the number of reactive effector
T cells in tolerant recipients (Li et al., 1999; Wells et al., gant experiment demonstrates that regulatory cells are
inherently capable of inducing as well as maintaining1999; Wekerle et al., 2001). If apoptosis is blocked in
these models by either removal of IL-2 from the system tolerance, although the sheer number of them required
to do so may explain why experiments designed to use(using T cells from IL-2-deficient mice) (Wells et al.,
1999), by enforcing the expression of Bcl-xL in T cells in vivo immune deviation to tolerize across an MHC
barrier have failed. Moreover, the expansion of large(Wells et al., 1999; Wekerle et al., 2001), or by coincident
treatment with the immunosuppressive drug cyclo- numbers of regulatory cells in vivo may require the death
of other cytopathic cells in the primary host. The lessonsporine A (Li et al., 1999), peripheral T cell deletion is
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we draw from these systems is that the capacity of ther- PCD (or death by neglect), in a sense, the opposite
apeutic intervention to induce tolerance is tightly associ- end of the spectrum for the activated T cells, illustrates
ated with the size of the antigen-reactive T cell pool. the exquisite dependence of activated T cells upon
The central prediction of this “pool size” model is growth factor (e.g., IL-2, IL-4, IL-7, and/or IL-15) stimula-
that, while apoptosis of antigen-specific T cells may be tion for survival, as these cells undergo apoptosis if they
required for the induction of tolerance in a system where are stimulated to enter the cell cycle and then deprived
the precursor frequency is high, T cell apoptosis may not of growth factors (Figure 3). Apoptotic cell death in this
be required when the frequency of reactive T cells is low. instance is largely due to rapid downregulation of Bcl-2
One approach to address this issue is to compare the family antiapoptotic molecules following growth factor
requirement for apoptosis in the induction of tolerance withdrawal (Van Parijs and Abbas, 1998).
across major versus minor histocompatibility complex However, it may be overly simplistic to draw so sharp
barriers, where, as described above, the frequency of a distinction between AICD and PCD, as they share
reactive T cells is highly disparate. Experiments per- many features, including a requirement for cell activation
formed so far to this end have supported this prediction. and a central role for IL-2. IL-2 alone among the known
As described above, mice whose T cells are resistant T cell growth factors controls the susceptibility of acti-
to apoptosis (either because they are deficient in the vated T cells to Fas-mediated apoptosis through down-
production of IL-2 [Dai et al., 1998; Li et al., 1999] or IFN-g regulation of FLICE inhibitory protein (FLIP) (Refaeli et
[Konieczny et al., 1998] or because they constitutively al., 1998). FLIP dimerizes with Fas-associated death do-
express the survival factor Bcl-xL [Wells et al., 1999]) main (FADD) and/or caspase 8, which prevents the re-
cannot be rendered tolerant to fully MHC-mismatched cruitment of death effector caspases downstream of
allografts by costimulation blockade during transplan- FADD. Upon downregulation of FLIP by active IL-2 prim-
tation, apparently because the frequency of alloreac- ing, activated T cells then acquire the sensitivity to Fas-
tive, apoptosis-resistant T cells remains unusually high mediated apoptosis. Indeed, IL-2 knockout mice have
throughout the response. However, consistent with our a profound defect in Fas-mediated apoptosis (Kneitz et
prediction, long-term acceptance of minor histocompat- al., 1995). However, it is likely that IL-2 regulates the
ibility complex–mismatched grafts can be achieved in competence of other death pathways to induce T cell
Bcl-xL transgenic or IFN-g-deficient mice subjected to apoptosis as well, as mice with defective Fas or FasL
costimulatory blockade (our unpublished data), sug- pathways remain susceptible to tolerance induction,
gesting that apoptosis is not required for the induction whereas IL-2 knockout mice are relatively resistant (Dai
of tolerance when the size of the alloreactive T cell pool et al., 1998; Li et al., 1999). This finding, namely that Fas
is very small. Together, the studies described above argue is not required for the deletional component of periph-
for a model in which apoptosis is required to reduce the eral tolerance strategies, stands in contrast to the stud-
size of a large reactive T cell pool to a level at which ies cited above showing that Fas is critical to the estab-
other mechanisms of immunologic tolerance, such as lishment of central tolerance through mixed chimerism
anergy and active immunoregulation, can control the (George et al., 1998).
otherwise destructive response (Figure 2). In addition to regulating apoptosis through Fas and
related death pathways, IL-2 is also instrumental in con-
Mechanisms for T Cell Death trolling the expression of the common cytokine receptor
What are the pathways through which apoptosis of T gc, a shared signaling component by receptors for IL-2,
cells can be mediated? In overtly lymphodepletive ap- IL-4, IL-7, IL-9, and IL-15 (Sugamura et al., 1996), follow-
proaches to tolerance induction, it is the manipulation ing multiple cell divisions (Dai et al., 1999; Demirci et
itself that directly kills recipient T cells. These are nonse- al., 2001). As the gc signal is critical to sustain Bcl-2
lective approaches in the sense that all mature recipient and/or Bcl-xL expression and cell survival (Nakajima et
T cells are eliminated, both donor-reactive and T cells
al., 1997), decreased gc expression reduces sustained
of other specificities. However, as indicated above,
Bcl-2 expression and renders cells susceptible to apo-
strategies that are not inherently lymphoablative appear
ptotic cell death. This means that IL-2 may affect Bcl-2/to rely nonetheless on apoptosis of donor-reactive cells
Bcl-xL-regulated cell death via modulating the gc chain(Li et al., 1999; Wells et al., 1999). In these instances,
expression on cycling T cells.apoptosis is likely to be selective for donor-reactive
cells, as only activated cells are susceptible to death.
Apoptotic Death Promotes ImmunoregulationApoptosis under these circumstances can be broadly
Recent studies suggest that apoptosis not only elimi-categorized into activation-induced cell death (AICD)
nates potentially destructive T cells but also promotesand passive cell death (PCD). AICD has been recognized
immunologic tolerance by facilitating the developmentfor many years and refers to the susceptibility of acti-
of an immunoregulatory state. One way that apoptosisvated and repetitively stimulated T cells to undergo apo-
might achieve this is by serving as a selective pressureptosis. The first described and probably most important
for regulatory T cells. For instance, apoptosis inducedmediator of AICD in T cells is the Fas receptor. Activated
by costimulatory blockade or rapamycin treatment isT cells induced to express the Fas molecule can undergo
largely dependent on cell division within the alloreactiveapoptotic cell death when brought into contact with cells
T cell pool (Li et al., 1999). While this mode of apoptosisexpressing Fas ligand (Figure 3). Even in the absence of
is efficient at eliminating alloreactive cytotoxic T lym-Fas, T cells can remain susceptible to AICD, most likely
phocytes (CTLs) and helper T cells, regulatory T cells aremediated through other members of the TNFR family,
largely nonproliferative and therefore may be resistant tosuch as death receptors (DR)3, DR4, and DR5 (Van Parijs
and Abbas, 1998). the apoptotic effects of these tolerance-inducing proto-
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Figure 3. In the Periphery, Donor-Reactive
Cells Can Undergo AICD or PCD in Either the
Allograft Itself or in Draining Lymph Nodes
After engraftment, passenger leukocytes con-
tained within the graft migrate to regional
lymph nodes (1) and initiate the allograft re-
sponse at that site (2) (Lakkis et al., 2000).
Primed alloreactive cells leave the node (3) and
enter the graft where they affect a response
(4). AICD may occur at either site and is driven
by continued antigenic stimulation. PCD would
be expected to occur away from the antigen
itself, either in a distinct compartment of the
lymph node (5) or at distant sites (6).
cols. In this way, apoptosis may directly select for T cells to suffer the fates of clonal deletion and anergy (Kurts et
al., 1997), perhaps due to the low levels of costimulatorycapable of mediating active immunoregulation.
Apoptosis may also facilitate the development of reg- molecules expressed by these cells (Figure 3). Both apo-
ptotic T cells and anergic T cells (Vendetti et al., 2000)ulatory T cells through its antiinflammatory effects. These
effects are typified in an ocular model of tolerance in inhibit DC maturation; thus, the induction of apoptotic
T cell deletion and anergy by immature DC may repre-which FasL expressed on ocular tissue inhibits local in-
flammation by directly killing activated T cells that at- sent a negative feedback loop, perpetuating a tolerant
state by opposing the maturation of new DC precursorstempt to infiltrate the intraocular space (Griffith et al.,
1996). Interestingly, this apoptotic process leads to the (Figure 4).
Therefore, in the ocular model, antigen presentationestablishment of stable, antigen-specific tolerance, and,
like transplantation tolerance, this state is systemic and to naive T cells by immature APCs in the presence of
IL-10 and TGF-b not only abrogates acute immunopa-is enforced by regulatory T cells. Also similar to trans-
plantation tolerance, if T cell apoptosis is blocked in this thology but also favors the development of suppressor
T cells and an immunoregulatory environment (Steinmanmodel, both systemic tolerance and ocular immune privi-
lege fail. But how might T cell apoptosis contribute directly et al., 2000). Whether apoptosis functions similarly dur-
ing transplantation tolerance is unclear, as studies haveto regulatory T cell development? It appears that, in addi-
tion to directly eliminating potentially pathologic T cells, not directly addressed whether T cells dying in the periph-
ery during an alloimmune response specifically induceapoptosis further promotes tolerance by inducing the
production of the antiinflammatory cytokines IL-10 and the production of antiinflammatory cytokines or even
whether there is a clear role for DC maturation in theTGF-b (Gao et al., 1998) and by directly suppressing the
immunostimulatory capacity of APCs (Steinbrink et al., decision between tolerance and rejection. However, re-
sults from the apoptosis-resistant T cell models de-1997). In addition, apoptotic cells do not support den-
dritic cell (DC) maturation, a process required by these scribed above may indicate that modulation of APC mat-
uration is a significant event during the induction ofAPCs to become competent to stimulate naive T cells.
Immature DC that take up antigen in the presence of transplantation tolerance. As mentioned, inhibition of
T cell apoptosis during costimulatory blockade was un-inflammatory stimuli (such as proinflammatory cyto-
kines, bacterial lipopolysaccheride [LPS], or necrotic able to oppose the long-term acceptance of minor-mis-
matched allografts. While one difference between thetissue) differentiate into APCs with high levels of T cell
stimulatory receptors, such as MHC, CD80, and CD86 alloimmune response against major versus minor histo-
compatibility complex antigens is the vast disparity in(Banchereau et al., 2000) (Figure 4). Conversely, imma-
ture DC that engulf antigen in the form or presence of the frequency of reactive T cells, another important dif-
ference is the pathway of alloantigen presentation thatapoptotic cell debris do not upregulate MHC or costimu-
latory molecules and fail to support productive T cell operates under each condition. Unlike major histocom-
patibility complex antigens, donor-derived minor histo-responses (Steinman et al., 2000). In fact, naive T
cells that encounter immature, antigen-bearing DC tend compatibility complex antigens must be processed and
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Figure 4. Apoptosis Promotes the Development of Immunoregulation
Naive T cells that encounter mature, antigen-bearing DCs are activated to proliferate and differentiate into effector cells capable of producing
proinflammatory cytokines (cycle on right). In addition to these soluble inflammatory mediators, activated T cells also provide cognate signals
for DC maturation in the form of CD40/CD40L interactions and for DC survival through TRANCE/TRANCE-R interactions (Banchereau et al.,
2000). Thus, the generation of an expanded pool of differentiated effector T cells by mature DC forms a positive feedback loop, promoting
both the maturation of new DC precursors and the extended survival of mature DC. Conversely, DC that take up antigen in the absence of
inflammatory stimuli remain immature (cycle on left). In the case of apoptosis, phosphatidylserine expressed on the surface of apoptotic cells
binds to a specific receptor on APCs, promoting the release of antiinflammatory cytokines. These APCs fail to support full activation,
proliferation, differentiation, and survival of naive T cells and instead tend to induce clonal anergy and deletion. Anergic and apoptotic T cells
generated during this process actively oppose further DC maturation, which reinforces the tolerant state.
presented to peptide-specific T cells by recipient- lytic biologics) are used as the principal treatment mo-
dality. In addition, overly intense immunosuppressionderived APC. This mode of “cross-priming” by recipient
APC is a potent mechanism by which self-tolerance to will block the acquisition of peripheral tolerance be-
cause induction of tolerance is an active antigen-drivenparenchymal autoantigens is maintained in models of
autoimmunity (Kurts et al., 1997) and therefore may T cell–dependent process. For example, the combined
use of calcineurin inhibitors that block signal 1 plusalso facilitate the induction of tolerance to minor-mis-
matched allografts in this transplantation model (Wells costimulation blockade that blocks signal 2 causes near
total immunosuppression in mice and thereby blocksand Turka, 2001). Furthermore, the “decommissioning”
of DC by apoptotic cell debris is reminiscent of the expression of IL-2, Ag-triggered T cell AICD, and
outgrowth of regulatory cells. Following cessation oftransplantation-associated phenomena of linked sup-
pression and infectious tolerance (Waldmann and Cob- this intense therapy, acute rejection occurs. In contrast,
the use of rapamycin, an agent that blocks the prolifera-bold, 1998). While it remains to be clearly demonstrated
in models of transplantation, it is likely that apoptosis tive signals delivered by T cell growth factors but not
IL-2-triggered apoptotic signals, in combination withof alloreactive T cells during the induction of tolerance
to allografts may facilitate the maintenance of tolerance costimulation blockade provides strong synergy as a
means to foster peripheral tolerance (Li et al., 1999).by inhibiting the maturation of DC and favoring the de-
velopment of an active immunoregulatory state. Anti-CD25 mAb treatment is a useful and safe adjunct
to conventional immunosuppression. In some experi-
mental allograft models, targeting CD25 or the high-Clinical Implications
In order to achieve central tolerance, long-lasting and affinity IL-2R complex with IgM antibodies or toxins can
produce transplant tolerance (Strom et al., 1992). Toler-massive deletion of donor-specific T cells can be achieved
by intense immunosuppression and creation of a mixed ance occurs because these specific agents kill many
IL-2R1-activated T cells, as nonlytic anti-CD25 mAbsdonor–recipient chimeric state. To achieve peripheral
tolerance, more subtle forms of immunosuppression are fail to produce tolerance. In clinical practice, the anti-
CD25 mAbs available are IL-2 receptor antagonists andrequired in order to preserve T cell apoptosis. IL-2-
dependent AICD is required to deplete alloreactive T have, by comparison with agents used in murine sys-
tems, a diminished capacity to directly kill CD251 T cells.cells if nondepletive therapies (e.g., drugs or noncyto-
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eic plus allogeneic or xenogeneic bone marrow leads to specificNonlytic anti-CD25 mAbs block IL-2-triggered apoptosis
acceptance of allografts or xenografts. Nature 307, 168–170.in a murine model (Demirci et al., 2001). In short, the
Kneitz, B., Herrmann, T., Yonehara, S., and Schimpl, A. (1995). Nor-ability of anti-CD25 mAbs to aid the induction of periph-
mal clonal expansion but impaired Fas-mediated cell death anderal tolerance hangs on the balance of their (untested)
anergy induction in interleukin-2-deficient mice. Eur. J. Immunol.
ability to directly kill IL-2R1 T cells versus their capacity 25, 2572–2577.
to block IL-2-mediated apoptosis.
Konieczny, B.T., Dai, Z., Elwood, E.T., Saleem, S., Linsley, P.S.,
The classical separation between deletional central Baddoura, F.K., Larsen, C.P., Pearson, T.C., and Lakkis, F.G. (1998).
tolerance and peripheral nondepletive tolerant states IFN-gamma is critical for long-term allograft survival induced by
blocking the CD28 and CD40 ligand T cell costimulation pathways.may be somewhat artificial. It seems likely that central
J. Immunol. 160, 2059–2064.tolerance is rarely created through complete and total
Kuchroo, V.K., Das, M.P., Brown, J.A., Ranger, A.M., Zamvil, S.S.,clonal deletion alone but that immunoregulatory pro-
Sobel, R.A., Weiner, H.L., Nabavi, N., and Glimcher, L.H. (1995). B7-1cesses arise to control “escaped” thymic emigrants.
and B7-2 costimulatory molecules activate differentially the Th1/Conversely, in peripheral strategies that are not inher-
Th2 developmental pathways: application to autoimmune disease
ently lymphoablative, clonal depletion may be a prereq- therapy. Cell 80, 707–718.
uisite to allow immunoregulation to emerge and be ef- Kurts, C., Kosaka, H., Carbone, F.R., Miller, J.F., and Heath, W.R.
fective. Thus, in the setting of the allograft response, (1997). Class I-restricted cross-presentation of exogenous self-anti-
immunoregulation and clonal depletion are inextricably gens leads to deletion of autoreactive CD8(1) T cells. J. Exp. Med.
186, 239–245.linked. We believe that the classical definitions of central
and peripheral transplant tolerance that appear to form Lakkis, F.G., Arakelov, A., Konieczny, B.T., and Inoue, Y. (2000).
Immunologic ‘ignorance’ of vascularized organ transplants in theextreme and opposing ends of a spectrum actually em-
absence of secondary lymphoid. Nat. Med. 6, 686–688.body interactive, not alternative, means of creating
Li, X.C., Zand, M.S., Li, Y., Zheng, X.X., and Strom, T.B. (1998). Ontransplant tolerance.
histocompatibility barriers, Th1 to Th2 immune deviation, and the
nature of the allograft responses. J. Immunol. 161, 2241–2247.
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